Affordable Access

Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up

Authors
  • TARDIVON, Coralie
  • Desmée, Solène
  • Kerioui, Marion
  • Bruno, René
  • Wu, Benjamin
  • Mentré, France
  • Mercier, François
  • Guedj, Jérémie
Publication Date
Apr 15, 2019
Source
HAL
Keywords
Language
English
License
Unknown
External links

Abstract

We characterized the association between tumor size kinetics and survival in advanced urothelial cancer patients treated with atezolizumab (anti-programmed death-ligand 1 (PD-L1), Tecentriq) using a joint model. The model, developed on data from 309 patients of a phase 2 clinical trial, identified the time-to-tumor growth and the instantaneous changes in tumor size as the best on-treatment predictors of survival. On the validation dataset containing data from 457 patients from a phase 3 study, the model predicted individual survival probability using 3 or 6-months tumor size follow-up data with an area under the receptor-occupancy curve between 0.75 and 0.84 as compared to values comprised between 0.62 and 0.75 when the model included only information available at treatment initiation. Including tumor size kinetics in a relevant statistical framework improve the prediction of survival probability during immunotherapy treatment, and may be useful to identify most-at-risk patients in "real-time". This article is protected by copyright. All rights reserved.

Report this publication

Statistics

Seen <100 times